Dynavax (DVAX) Rockets 38% on Sanofi $2-Billion Merger

Core Viewpoint - Dynavax Technologies Corp. is set to be acquired by Sanofi for $2.2 billion, leading to a significant increase in its stock price by 38.19% to $15.38 on the announcement day [1][5]. Group 1: Acquisition Details - Dynavax has officially entered into an agreement with Sanofi to acquire all outstanding shares at a price of $15.50 each, representing a premium of approximately 39% over its closing price on December 23 [2]. - The acquisition will enhance Sanofi's presence in adult immunization, particularly through Dynavax's adult hepatitis B vaccine, Heplisav-B, which offers a two-dose regimen that provides faster seroprotection compared to traditional three-dose vaccines [3]. Group 2: Vaccine Portfolio and Development - The acquisition includes Dynavax's shingles vaccine candidate (Z-1018), currently in phase 1/2 clinical development, along with other vaccine pipeline projects [4]. - Dynavax's CEO emphasized that joining Sanofi will leverage global scale and expertise to maximize the impact of their vaccine portfolio, addressing significant public health needs [5].